150 related articles for article (PubMed ID: 33902413)
21. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Squires K; Kityo C; Hodder S; Johnson M; Voronin E; Hagins D; Avihingsanon A; Koenig E; Jiang S; White K; Cheng A; Szwarcberg J; Cao H
Lancet HIV; 2016 Sep; 3(9):e410-e420. PubMed ID: 27562742
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial.
Hosogaya N; Miyazaki T; Fukushige Y; Takemori S; Morimoto S; Yamamoto H; Hori M; Kurokawa T; Kawasaki Y; Hanawa M; Fujii Y; Hanaoka H; Iwami S; Watashi K; Yamagoe S; Miyazaki Y; Wakita T; Izumikawa K; Yanagihara K; Mukae H; Kohno S;
Trials; 2021 Apr; 22(1):309. PubMed ID: 33910617
[TBL] [Abstract][Full Text] [Related]
23. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
24. Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.
Lima VD; Nosyk B; Wood E; Kozai T; Zhang W; Chan K; Montaner JS
AIDS; 2012 Jul; 26(12):1491-500. PubMed ID: 22555161
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
[TBL] [Abstract][Full Text] [Related]
26. Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Wongprikorn A; Sukasem C; Puangpetch A; Numthavej P; Thakkinstian A; Kiertiburanakul S
PLoS One; 2016; 11(6):e0157531. PubMed ID: 27304841
[TBL] [Abstract][Full Text] [Related]
27. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
[TBL] [Abstract][Full Text] [Related]
28. No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Perrier M; Visseaux B; Landman R; Joly V; Todesco E; Yazdanpanah Y; Calvez V; Marcelin AG; Descamps D; Charpentier C
J Antimicrob Chemother; 2018 Jan; 73(1):173-176. PubMed ID: 29077926
[TBL] [Abstract][Full Text] [Related]
29. Non-Hodgkin's lymphoma after prolonged remission of Hodgkin's disease in an HIV-infected patient.
Montalban C; Bellas C; Rodriguez-Garcia JL; Aguado M; Fernandez-Muñoz R
Ann Oncol; 1991 Sep; 2(8):585-7. PubMed ID: 1665342
[TBL] [Abstract][Full Text] [Related]
30. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
Wei J; Zhao J; Han M; Meng F; Zhou J
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
[TBL] [Abstract][Full Text] [Related]
31. Successful Treatment for Isolated Bone Marrow Hodgkin Lymphoma in an Human Immunodeficiency Virus (HIV)-Negative Patient.
Odeh R; Hamayel HF
Am J Case Rep; 2022 Feb; 23():e935045. PubMed ID: 35185147
[TBL] [Abstract][Full Text] [Related]
32. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Antunes F
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):569-576. PubMed ID: 28443391
[TBL] [Abstract][Full Text] [Related]
33. False-positive for SARS-CoV-2 antigen test in a man with acute HIV infection.
Yamaniha K; Kinjo T; Akamine M; Setoguchi M; Tateyama M; Fujita J
J Infect Chemother; 2021 Jul; 27(7):1112-1114. PubMed ID: 33902991
[TBL] [Abstract][Full Text] [Related]
34. HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect.
Foo CS; Abdelnabi R; Kaptein SJF; Zhang X; Ter Horst S; Mols R; Delang L; Rocha-Pereira J; Coelmont L; Leyssen P; Dallmeier K; Vergote V; Heylen E; Vangeel L; Chatterjee AK; Annaert PP; Augustijns PF; De Jonghe S; Jochmans D; Gouwy M; Cambier S; Vandooren J; Proost P; van Laer C; Weynand B; Neyts J
Antiviral Res; 2022 Jun; 202():105311. PubMed ID: 35390430
[TBL] [Abstract][Full Text] [Related]
35. Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
Di Biagio A; Rosso R; Loregian A; Pagni S; Sormani MP; Cenderello G; Palù G; Viscoli C
J Infect Chemother; 2012 Aug; 18(4):587-90. PubMed ID: 22422300
[TBL] [Abstract][Full Text] [Related]
36. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
[TBL] [Abstract][Full Text] [Related]
38. Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Lombardi F; Belmonti S; Quiros-Roldan E; Latini A; Castagna A; D'Ettorre G; Gagliardini R; Fabbiani M; Cauda R; De Luca A; Di Giambenedetto S;
J Antimicrob Chemother; 2017 Jul; 72(7):2055-2059. PubMed ID: 28333353
[TBL] [Abstract][Full Text] [Related]
39. Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Simpson KN; Luo MP; Chumney EC; King MS; Brun S
Clin Drug Investig; 2007; 27(1):67-74. PubMed ID: 17177581
[TBL] [Abstract][Full Text] [Related]
40. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation.
Schmitz N; Dreger P; Zander AR; Ehninger G; Wandt H; Fauser AA; Kolb HJ; Zumsprekel A; Martin A; Hecht T
Bone Marrow Transplant; 1995 Feb; 15(2):261-6. PubMed ID: 7539668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]